Zelira Therapeutics Ltd (ZLD) - Total Assets

Latest as of June 2025: AU$1.30 Million AUD ≈ $920.32K USD

Based on the latest financial reports, Zelira Therapeutics Ltd (ZLD) holds total assets worth AU$1.30 Million AUD (≈ $920.32K USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore cash flow to debt ratio of Zelira Therapeutics Ltd to assess how comfortably operating cash covers total debt obligations.

Zelira Therapeutics Ltd - Total Assets Trend (2004–2025)

This chart illustrates how Zelira Therapeutics Ltd's total assets have evolved over time, based on quarterly financial data. See Zelira Therapeutics Ltd net assets for net asset value and shareholders' equity analysis.

Zelira Therapeutics Ltd - Asset Composition Analysis

Current Asset Composition (June 2025)

Zelira Therapeutics Ltd's total assets of AU$1.30 Million consist of 47.2% current assets and 52.8% non-current assets.

Asset Category	Amount (AUD)	% of Total Assets
Cash & Equivalents	AU$0.00	0.4%
Accounts Receivable	AU$4.69K	0.4%
Inventory	AU$477.91K	36.7%
Property, Plant & Equipment	AU$121.85K	9.4%
Intangible Assets	AU$520.63K	40.0%
Goodwill	AU$0.00	0.0%

Asset Composition Trend (2004–2025)

This chart illustrates how Zelira Therapeutics Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Zelira Therapeutics Ltd worth.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Zelira Therapeutics Ltd's current assets represent 47.2% of total assets in 2025, an increase from 29.4% in 2004.
Cash Position: Cash and equivalents constituted 0.4% of total assets in 2025, down from 25.2% in 2004.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 40.0% of total assets, an increase from 0.0% in 2004.
Asset Diversification: The largest asset category is intangible assets at 40.0% of total assets.

Zelira Therapeutics Ltd Competitors by Total Assets

Key competitors of Zelira Therapeutics Ltd based on total assets are shown below.

Company	Country	Total Assets
Tubize-Fin BR:TUB	Belgium	€1.93 Billion
Verona Pharma plc F:I9SA	Germany	€572.87 Million
Xiamen Amoytop Biotech Co Ltd SHG:688278	China	CN¥3.21 Billion
Syndax Pharmaceuticals Inc NASDAQ:SNDX	USA	$472.67 Million
Neuren Pharmaceuticals Ltd AU:NEU	Australia	AU$331.25 Million
Vor Biopharma Inc NASDAQ:VOR	USA	$506.75 Million
Chengdu Kanghua Biological Products SHE:300841	China	CN¥3.94 Billion
Jiangsu Aidea Pharmaceutical Co Ltd SHG:688488	China	CN¥1.84 Billion

Zelira Therapeutics Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	0.11	0.60	2.73
Quick Ratio	0.02	0.42	2.73
Cash Ratio	0.00	0.00	2.53
Working Capital	AU$-4.98 Million	AU$-2.83 Million	AU$1.16 Million

Zelira Therapeutics Ltd - Advanced Valuation Insights

This section examines the relationship between Zelira Therapeutics Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	0.32
Latest Market Cap to Assets Ratio	3.24
Asset Growth Rate (YoY)	-74.9%
Total Assets	AU$1.30 Million
Market Capitalization	$4.21 Million USD

Valuation Analysis

Premium Asset Valuation: The market values Zelira Therapeutics Ltd's assets at a significant premium (3.24x), suggesting investors see substantial growth potential or unique competitive advantages.

Significant Asset Reduction: Zelira Therapeutics Ltd's assets decreased by 74.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.

Annual Total Assets for Zelira Therapeutics Ltd (2004–2025)

The table below shows the annual total assets of Zelira Therapeutics Ltd from 2004 to 2025.

Year	Total Assets	Change
2025-06-30	AU$1.30 Million ≈ $920.32K	-74.91%
2024-06-30	AU$5.18 Million ≈ $3.67 Million	-84.71%
2023-06-30	AU$33.89 Million ≈ $23.98 Million	-10.11%
2022-06-30	AU$37.70 Million ≈ $26.68 Million	-4.23%
2021-06-30	AU$39.37 Million ≈ $27.85 Million	+9.99%
2020-06-30	AU$35.79 Million ≈ $25.32 Million	+918.11%
2019-06-30	AU$3.52 Million ≈ $2.49 Million	-44.33%
2018-06-30	AU$6.31 Million ≈ $4.47 Million	-20.75%
2017-06-30	AU$7.97 Million ≈ $5.64 Million	+9003.45%
2016-06-30	AU$87.52K ≈ $61.92K	-78.56%
2015-06-30	AU$408.27K ≈ $288.87K	-47.67%
2014-06-30	AU$780.16K ≈ $552.02K	-27.66%
2013-06-30	AU$1.08 Million ≈ $763.11K	-24.66%
2012-06-30	AU$1.43 Million ≈ $1.01 Million	+63.54%
2011-06-30	AU$875.29K ≈ $619.33K	+25.95%
2010-06-30	AU$694.95K ≈ $491.72K	-80.41%
2009-06-30	AU$3.55 Million ≈ $2.51 Million	+153.52%
2008-06-30	AU$1.40 Million ≈ $990.04K	-84.91%
2007-06-30	AU$9.27 Million ≈ $6.56 Million	-64.95%
2006-06-30	AU$26.45 Million ≈ $18.72 Million	+163.92%
2005-06-30	AU$10.02 Million ≈ $7.09 Million	+17.33%
2004-06-30	AU$8.54 Million ≈ $6.04 Million	--

About Zelira Therapeutics Ltd

AU:ZLD Australia Biotechnology

Market Cap

$4.21 Million

AU$5.95 Million AUD

Market Cap Rank

#28865 Global

#1565 in Australia

Share Price

AU$0.50

Change (1 day)

+0.00%

52-Week Range

AU$0.31 - AU$0.91

All Time High

AU$26.25